Literature DB >> 8177094

Urinary excretion of pyridinium crosslinks of collagen in oophorectomized women as markers for bone resorption.

K Hashimoto1, M Nozaki, M Yokoyama, M Sano, H Nakano.   

Abstract

To detect increased bone resorption in estrogen-deficient women, the urinary excretion of hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP), which are intermolecular crosslinkings of collagen fibers, were measured and their chronological changes were evaluated following oophorectomy. Seventy-five women were divided into three groups; 15 premenopausal women (mean age 44.0 years), 15 postmenopausal women (mean age 54.2 years) and 45 surgically menopausal women who had a normal menstrual cycle before surgery (mean age 42.2 years). There was a significant increase in HP and LP of the postmenopausal women (P < 0.001). In the oophorectomized women, both HP and LP were three times higher than those of premenopausal women within 1 year after oophorectomy, and decreased to the same level of the postmenopause between 2 and 3 years after surgery. In the six oophorectomized women after the administration of estrogen, HP and LP both decreased remarkably in all cases. The present study thus indicates that an increase of bone resorption which was evaluated by urinary HP and LP occurs in the early stage after oophorectomy. It may, therefore, be good to begin estrogen replacement therapy as soon as possible after oophorectomy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8177094     DOI: 10.1016/0378-5122(94)90051-5

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  3 in total

1.  Predicting the effects of estrogen replacement therapy on lumbar bone mineral density in oophorectomized women: analysis of a 10-year longitudinal study.

Authors:  Hideaki Nagata; Masahiro Nozaki; Hitoo Nakano
Journal:  Osteoporos Int       Date:  2003-10-08       Impact factor: 4.507

2.  Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosis.

Authors:  Markus J Seibel
Journal:  Clin Biochem Rev       Date:  2006-08

3.  Combination of intermittent cyclical etidronate and hormone replacement therapy for postmenopausal non-responders to estrogen.

Authors:  M Nozaki; K Koera; R Egami; H Nagata; H Nakano
Journal:  Clin Drug Investig       Date:  2002       Impact factor: 2.859

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.